This study aimed to assess the effects of sugammadex and neostigmine/atropine on postoperative cognitive dysfunction (POCD) in adult patients after elective surgery. A randomised, double-blind controlled trial was carried out on 160 American Society of Anesthesiologists physical status I to III patients who were >40 years of age. The Mini-Mental State Evaluation, clock-drawing test and the Isaacs Set test were used to assess cognitive function at three timepoints: 1) preoperatively, 2) one hour postoperatively, and 3) at discharge. The anaesthetic protocol was the same for all patients, except for the neuromuscular block reversal, which was administered by random allocation using either sugammadex or neostigmine/ atropine after the reappearance of T2 in the train-of-four sequence. POCD was defined as a decline ≥1 standard deviation in ≥2 cognitive tests. The incidence of POCD was similar in both groups at one hour postoperatively and at discharge (28% and 10%, in the neostigmine group, 23% and 5.4% in the sugammadex group, P=0.55 and 0.27 respectively). In relation to individual tests, a significant decline of clock-drawing test in the neostigmine group was observed at one hour postoperatively and at discharge. For the Isaacs Set test, a greater decline was found in the sugammadex group. These findings suggest that there are no clinically important differences in the incidence of POCD after neostigmine or sugammadex administration.
an impairment of memory, concentration and intellectual abilities, is a well-known complication after both cardiac and non-cardiac operations [1] [2] [3] [4] [5] [6] . Various studies have observed that the incidence of this condition ranges from 10% to 65% postoperatively 7, 8 and is influenced by factors such as type of surgery 1, [9] [10] [11] [12] [13] , the age of patients 14, 15 , and the timing of postoperative cognitive examination 1, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . Despite extensive investigation [27] [28] [29] [30] [31] , firm conclusions that link risk factors to the development and duration of this condition remain elusive.
The cholinergic system plays a notable role in the decline of cognitive function, through nicotinic acetylcholine receptors, which are involved in chemical signalling and regulation of consciousness, memory and learning 1, 12, [32] [33] [34] [35] [36] . A central cholinergic deficit caused by disturbances in the cholinergic transmission due to perioperative administration of anticholinergic drugs has been implicated as a possible cause of POCD 16, 22, 33, 36 .
The practice of reversing neuromuscular blockade at the end of surgery by administration of an anticholinesterase in combination with an anticholinergic agent raises the question of whether such drugs may also interfere with postoperative cognition. This question is especially pertinent for anticholinergic agents that are capable of crossing the blood-brain barrier. Sugammadex, a recently introduced drug that specifically reverses the effects of aminosteroids, acts through a novel mechanism that encapsulates the neuromuscular drug and does not affect acetylcholine function at the neuromuscular junction [37] [38] [39] . In light of the above, the aim of this study was to examine the hypothesis that sugammadex is associated with a reduced incidence of POCD as compared to neostigmine/atropine in combination when used for reversal of rocuronium in adult patients undergoing elective surgery.
Materials and methods
The study followed a prospective, randomised, double-blind controlled trial format and was conducted after approval from the Scientific and Ethics Committee of Attikon University Hospital, Athens, Greece (331/21-9-2010, 24/9/2010, Prof. Liapis C). The study was conducted in accordance with the Ethical Principles for Medical Research Involving Human Subjects as outlined in the Declaration of Helsinki and has been registered at ClinicalTrials.gov (NCT02419352). All patients were fully informed about the study protocol and provided written informed consent.
Only patients who passed certain criteria were eligible for inclusion: 1) age >40 years, 2) American Society of Anesthesiologists physical status I to III, 3) fluent in Greek with the ability to read, and 4) scheduled to undergo elective surgery under general anaesthesia with or without an epidural. The age group >40 years of age was selected in order to focus on middle-aged and elderly patients. Patients undergoing neurosurgical, cardiac, vascular or orthopaedic procedures were excluded, as these procedures carry an increased risk of POCD. Additional exclusion criteria included the presence of other factors known to affect the incidence of POCD or factors that affect the ability to obtain accurate neuropsychological data, such as 1) any prior history involving an affliction of the central nervous system, 2) a preoperative Mini-Mental State Evaluation (MMSE) <22, 3) a serious hearing or visual impairment, 4) psychiatric disorders, 5) alcoholism or drug dependence, 6) regular medication with tranquillisers and/or antidepressants, 7) any known allergies to the drugs included in the protocol, and 8) patient refusal.
The tests that were administered to the study group were selected after a thorough perusal of available literature and were based on the following specific criteria: 1) they should require a short time for administration, 2) should be simple enough to guarantee the maximum cooperation of patients during the perioperative period, 3) should assess different domains of cognition (memory, learning, attention, psychomotor coordination, executive function) and be able to detect cognitive impairment with good sensitivity and specificity in a perioperative setting 25, 40, 41 . The MMSE 18,24 is a well-accepted measure of global cognitive function that has sensitivity and specificity values of 80% to 95% and 86% to 100%, respectively 40 . Despite its obvious limitations (ceiling effect, performance affected by age and education), it is by far the most popular cognitive test in clinical practice and is regarded as a gold standard for all cognitive screening tools in a perioperative setting 42, 43 . The clock-drawing test (CDT), with a sensitivity and specificity of 85% 44, 45 , requires verbal understanding, memory and coded knowledge apart from visuoconstructive skills 46 . It is regarded as highly acceptable by patients, correlates well with the MMSE and is useful in examining cognitive domains that are not evaluated by the MMSE 45, 47 . The verbal fluency assessment (Isaacs Set test [IST]) 42, 48 test is often combined with the MMSE and CDT as it can help in the early detection of cognitive impairment 45 , with the additional advantage of objective scoring and lack of ceiling or floor effect 42 .
In order to plan the sample size, previous studies on cognitive function were used: Schoen J et al 9 (128 patients for two groups), Chen X et al 10 .0]). The largest sample size (of 141 patients in total) was selected, in order to obtain a statistical power of at least 80% for cognitive decline detection, regardless of groups, and that would also be in accordance with previous studies 9, 10, 18, 29 . This number was increased to 160 patients for both groups, in order to account for possible dropouts. The two groups received either sugammadex or neostigmine/atropine, as per a computer-based randomisation process.
After the preanaesthetic evaluation, the cognitive function of the patients was assessed using the three neuropsychological tests outlined above 40, [42] [43] [44] [45] [47] [48] [49] [50] [51] [52] . POCD was defined as a decline equal to or more than one SD in at least two of the three cognitive tests performed, as mentioned in previous studies 7, 24, 25, 41, 53 . The researcher who performed the preoperative cognitive assessment also enrolled the participants and allocated them to the intervention procedure.
The protocol followed for induction and maintenance of anaesthesia was the same for both groups. All patients received 1 mg midazolam intravenously (IV) as premedication. Anaesthesia was induced by administration of propofol 2 to 2.5 mg/kg IV, fentanyl 2 μg/kg IV and rocuronium 0.8 mg/kg IV. Rocuronium was administered after calibration of the accelerometry device that was placed on the ulnar nerve of the hand opposite to the one used for intravenous drug administration (train-of-four [TOF] watch, Organon, Ireland). Anaesthesia was maintained using sevoflurane titrated to achieve a bispectral index score of 40 to 50. Intermittent doses of rocuronium were administered to maintain sufficient muscle relaxation when TOF reached >3 detectable twitches. In cases where general anaesthesia alone was used, the patients received an infusion of remifentanil that had been titrated as per clinical requirements, along with morphine 0.05 to 0.1 mg/kg 30 minutes before the end of the procedure for postoperative analgesia. In cases where a combination of general and epidural anaesthesia was used, analgesia was achieved with epidural administration of fentanyl 50 to 100 μg and ropivacaine (0.5% to 0.75%). In both groups, all patients received additional paracetamol 1 g 30 minutes prior to the end of the procedure and non-steroidal anti-inflammatory drugs were administered without restriction dependent upon the discretion of the anaesthetist in charge.
At the end of surgery, sevoflurane administration and remifentanil infusion (whenever used) were stopped and, after reappearance of the T2 in the TOF sequence and achievement of a bispectral index score value >80, residual neuromuscular blockade was reversed with administration of either sugammadex (2 mg/kg) or neostigmine/atropine (neostigmine 0.04 mg/kg combined with 0.4 mg atropine for each milligram of neostigmine administered) 54 . Each drug was diluted in 5 ml saline so as to appear identical. Care was taken so as to ensure that the anaesthesiologist in charge was not aware of what reversal drug was to be used. After extubation, the patients were transferred to the postanaesthesia care unit where their cognitive function was reassessed at one hour postoperatively. Verbal pain scores (Numerical Rating Scale ranging from 0=no pain to 10=most severe pain) were recorded, and pain was treated accordingly such that the cognitive evaluation was performed with scores of <5. The cognitive functions were re-evaluated at the time of hospital discharge or on the seventh day postoperatively if the patient was still hospitalised. All assessments were performed by a researcher who was not aware of the type of reversal agent administered to the patient concerned.
The primary aim of this study was to examine the hypothesis that sugammadex is associated with a reduced incidence of POCD as compared to neostigmine/atropine combination. Changes in the MMSE, CDT and IST profiles were also analysed separately to assess the individual cognitive domains covered by each test.
Statistical analysis
Normality was tested using the Shapiro-Wilk test. Normally distributed data were presented in terms of mean (±SD) while median and interquartile range (IQR) values have been used for describing data that do not follow a normal distribution. Normally distributed data were compared using Student's t-test. The data that were not normally distributed were compared using the Kruskal-Wallis test. Fisher's exact test was applied for comparison of categorical data. Statistical significance level was set at P <0.05 throughout the analysis. The analyses were conducted using the StataCorp 2013 software (Stata Statistical Software: Release 13. College Station, TX: StataCorp LP).
Results
A total of 177 patients were initially included in this study (September 2010 to December 2015). Seventeen patients withdrew due to consent issues, ongoing postoperative sedation or surgical or other complications. The final sample size of the study was 160 patients with 82 in the neostigmine group and 78 in the sugammadex group. The demographic data of all study subjects are presented in Table 1 .
Both groups were comparable with regard to age, sex, body mass index, American Society of Anesthesiologists physical status, education level, occupation, coexisting diseases, and history of previous general anaesthesia and surgery. With respect to perioperative and anaesthetic factors (Table 2 on next page), there were no intergroup differences except for the type of surgery performed (P=0.01), the postoperative analgesic requirements (P=0.036) and the days of hospitalisation (P=0.037). Upon evaluation of the cognitive functions, it was observed that the baseline scores obtained in the MMSE and IST tests were comparable for the two groups (27.24 and 32.05 in the neostigmine group and 27.08 and 32.32 in the sugammadex group, P=0.62 and 0.74, respectively). However, in CDT, the baseline scores of the neostigmine group were seen to be higher than that of the sugammadex group (3.5 and 3.15, respectively, P=0.01). As eight patients were discharged before the final set of tests could be conducted, only 152 patients were available for the evaluation of cognitive function at discharge.
A similar incidence of POCD was observed for the two groups with respect to at one hour postoperatively and at discharge (28% and 10% in the neostigmine group, 23% and 5.4% in the sugammadex group, P=0.55 and P=0. 27, respectively) . When separate test results were analysed, it was observed that scores for all three tests for the one hour postoperative timepoint were lower than baseline (P <0.05). The MMSE and IST values returned to baseline values at discharge (P <0.05), whereas the CDT values remained significantly decreased (Table 3) . One hour postoperatively, the MMSE score was decreased in both the neostigmine as well as the sugammadex groups. Although this difference was not statistically significant, the patients of the sugammadex group showed a smaller decline in their performance one hour postoperatively and a greater improvement at discharge despite their lower baseline assessment scores ( [3] [4] [5] [6] [7] 0.037* ‡Normally distributed data are presented as mean (standard deviation) and Student's t-test was applied for comparisons between groups. † Fisher's exact test was applied for contingency tables. ⱡ Not normally distributed data presented as median [interquartile range] and the Kruskal-Wallis test was applied for comparisons between groups. NRS, numerical rating scale score; ED, epidural; PCA, patient-controlled analgesia; NSAID, non-steroidal antiinflammatory drug. Aldrete, time in seconds to achieve score >9. Figure 1) . Regarding CDT, a decline was observed one hour postoperatively in both groups; this decrease was significantly greater in the neostigmine group at both timepoints (P=0.01 and 0.03 respectively [ Table 3 , Figure 2 ]. On the other hand, patients who received neostigmine performed better in the IST test as compared to those in the sugammadex group (P=0.02) (Table 3, Figure 3 ). No adverse reactions were observed in either group with respect to the reversal agent administered.
Discussion
The aim of this study was to assess the early postoperative cognitive function of adult patients who, as part of their general anaesthesia for elective surgery, had received either sugammadex or neostigmine/atropine, administered as a reversal agent for rocuronium. We hypothesised that sugammadex, which is a newer reversal agent for rocuronium, and which lacks anticholinergic activity, could possibly be associated with a lower incidence of POCD as compared to the traditional neostigmine/atropine combination. However, our findings suggest that there is no clinically important difference regarding the occurrence of postoperative POCD between the two groups. While the sugammadex group had superior scores for certain individual tests, such as the CDT and the MMSE, the IST values were better for the group that was administered the neostigmine/ atropine combination. Moreover, using our definition of POCD (a decline of more than 1 SD in at least two of the three cognitive tests performed), the incidences of POCD were similar.
The tests selected for this study were chosen for their ability to assess different domains of cognition and also because their sensitivity and specificity in a perioperative clinical setting are within the acceptable range 25, 40, 41 . There was no control group in this study. Instead, each participant acted as his/her own control 25 . Though the term 'sufficient decline' has seemingly subjective connotations, various studies have defined it as a decline of ≥1 SD when compared with the preoperative cognitive performance score on at least one or two neuropsychological tests 7, 24, 25, 41, 53 . An alternative approach is to assess the scores of the cognitive tests as continuous measures and express the degree of decline between specific timepoints 41 indicating alterations in different domains of cognition. The total incidence of POCD in this study was revealed to be 25% one hour after surgery and 7.8% at discharge. Taking into account the effect of multiple factors, such as varying definitions, different types of tests, different types of surgery and the time of assessment, this POCD incidence is in accordance with current literature 1, 11, 16, 17 . In the ISPOCD1 study conducted on patients >60 years of age after major non-cardiac surgery, the incidence of POCD was determined to be 26% one week after the surgery and 10% after three months. In middleaged patients, it was reported that the prevalence of POCD was much lower (19% at one week and 6% after three months) 8, 14, 19 .
With regard to intergroup differences within each test performance, the results did not support either reversal agent over the other. While the CDT results revealed that administration of sugammadex resulted in improved scores, MMSE scores were not significantly different. In contrast, in the IST evaluation, the neostigmine patients performed better. This fact cannot be explained on the basis of the current knowledge of the mechanism of action of the drugs administered and their relationship with POCD pathogenesis. It is to be noted, however, that IST evaluates verbal fluency, in which the speed component plays a key role, in contrast to MMSE and CDT, which do not. As sugammadex is a relatively new therapeutic agent, it is possible that the full range of its cognitive interactions are not fully understood. This warrants further investigation.
The degree of postoperative cognitive improvement in some patients is not surprising and this phenomenon has been previously reported in the literature. The brain is hypothesised to retain neuroplastic potential even in older patients 13 and, although controversial, it has been suggested that the potential for cognitive improvement after surgery exists. Opponents to this view believe that the improvement observed can be simply attributed to statistical artefacts or to the 'learning' effect 13, 41 .
The importance of the role played by the central cholinergic transmission in cognitive function, especially memory, orientation and attention, are well established 1, 12, 36 . Some research has indicated that acetylcholine depletion is associated with cognitive impairment and the development of dementia 22 , while the disturbed cholinergic transmission caused by perioperative administration of anticholinergic drugs could influence the pathogenesis of postoperative cognitive dysfunction 12, 35, 36 . Other factors implicated in postoperative cognitive decline include the type 3,5,7,21,24-26 , depth 7, 21, 26, 27 and duration 3,21 of anaesthesia, the anaesthetic drugs 10, 18, 26, [28] [29] [30] used, the type and duration of surgery 3, 7, 11, 14, 16, 25 , patient age 3, 4, 8, 9, 11, 12, 16, 19, 21, 25, 31 , educational level 3, 6, 9, 16, 19, 25, 31, 32 , and socioeconomic status 1,9 ; and several others such as reoperation, postoperative infection, inflammation, history of stroke, cardiovascular disease, alcohol consumption, low baseline cognition, obesity and American Society of Anesthesiologists physical status 1, 4, 10, 11, 13, 14, 19, 24, 28, 31, 33 . In the existing 'cognitive reserve' theory, differences in the ability of the brain to cope with stress or an insult have also been related to age and educational levels 1, 7, 9, 11, 13, 55 .
As for limitations of this study, there were baseline differences observed in the CDT scores and type of the surgery despite the randomisation. There was a higher prevalence of major surgery in the sugammadex group as well as a lower baseline CDT score, which could have confounded the results. We performed a large number of simultaneous comparisons and therefore cannot exclude a higher possibility of type I errors. We also cannot reliably exclude changes of <1 SD in the tests used. Furthermore, these findings would require confirmation in a larger study with testing that should extend for longer time periods, and ideally be stratified for surgical procedures and age groups.
In conclusion, the incidence of POCD following general anaesthesia for elective surgery in adult patients >40 years of age was similar whether sugammadex or neostigmine/ atropine was used for reversal of residual rocuroniuminduced neuromuscular block.
